Structure—Activity Relationships for Anti—Tumour Platinum Complexes

  • M. J. Cleare
Part of the Developments in Pharmacology book series (DIPH, volume 3)


Cis-dichlorodiammineplatinum(II) is now an established member in the armamentarium of anti-neoplastic agents. It is variously known as cisplatin (which is used in this paper) and neoplatin, depending on the country in which it is being sold. It is unique amongst the anti-cancer drugs in that it is based on a heavy metal, namely platinum.


Lewis Lung Platinum Complex Cross Resistance L1210 Tumour Alicyclic Amine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    B. Rosenberg, L. Van Camp and T. Krigas, Nature (London), 205, 698 (1965).CrossRefGoogle Scholar
  2. 2.
    B. Rosenberg, L. Van Camp, J.E. Trosko and V.H. Mansour, Nature (London), 222, 385 (1969).CrossRefGoogle Scholar
  3. 3.
    J.R. Durant in “Cisplatin: Current Status and New Developmets”, (Eds. A.W. Prestayko, S.T. Crooke and S.K. Carter), pg.317, Academic Press, 1980.Google Scholar
  4. 4.
    S.D. William and L.H. Einhorn in Reference (3), pg.323.Google Scholar
  5. 5.
    S. Seeber, M.E. Scheulen, R.B. Schilcher, M. Higi, N. Niederle, D. Mouratidou, W.C. Bierbaum and C.G. Schmidt, in Ref. (3), pg.329.Google Scholar
  6. 6.
    J.F. Holland, H.W. Bruckner, C.J. Cohen, R.C. Wallach, S.B. Gusberg, E.M. Greenspan and J. Goldberg, in Reference (3), pg.383.Google Scholar
  7. 7.
    E. Wiltshaw, Personal communication.Google Scholar
  8. 8.
    M.J. Cleare, P.C. Hydes, B.W. Malerbi and D.M. Watkins, Biochemie, 60, 835 (1978).CrossRefGoogle Scholar
  9. 9.
    M.J. Cleare, P.C. Hydes, D.R. Hepburn and B.W. Malerbi, in Ref. (3), pg.149.Google Scholar
  10. 10.
    F. Basolo and R.G. Pearson, Mechanisms of Inorganic Reactions, (2nd Ed) Wiley (New York), pg.359, 1967.Google Scholar
  11. 11.
    M.J. Cleare and J.D. Hoeschele, Bioinorg.Chem., 2, 187 (1973).CrossRefGoogle Scholar
  12. 12.
    M.J. Cleare and J.D. Hoeschele, Platinum Metals Review, 17, 2 (1973).Google Scholar
  13. 13.
    T.A. Connors, M. Jones, W.C.J. Ross, P.D. Braddock, A.R. Khokhar and M.L. Tobe, Chem-Biol. Interactions, 5, 415 (1972); ibid 11, 145 (1975).Google Scholar
  14. 14.
    M.K. Wolpert-De Filippes in Reference (3), pg.183.Google Scholar
  15. 15.
    G.K. Gale and S.J. Meischen, U.S. Patent Appl. No. 769,888.Google Scholar
  16. 16.
    W.T. Bradner, W.C. Rose and J.B. Huftalen, in Ref. (3), pg.171.Google Scholar
  17. 17.
    J. Berg, E.J. Bulten and F. Verbeek, U.K. Patent Appl. No. 2,024,823 A.Google Scholar
  18. 18.
    J.P. Macquet and J.P. Armand, Proc.Am.Assoc.Cancer Res., 22, 260 (1981); ibid 22, 261 (1981).Google Scholar
  19. 19.
    Y. Kidani, K. Okamato and R. Saito, U.S. Patent No. 4,255,347 (1981).Google Scholar
  20. 20.
    T. Totani and K. Yamaguchi, U.K. Patent Appt. No. 2,074,567 A (1981).Google Scholar
  21. 21.
    C. Yoshikumi, T. Fujii, K. Saito, M. Fujii and K. Niimura, European Patent Appl. No. 41,792 (1981).Google Scholar
  22. 22.
    W.C. Rose, J.E. Schurig, J.B. Huftalen and W.T. Bradner, in press.Google Scholar
  23. 23.
    E.J. Bulton and F. Verbeek, French Patent Appl. No. 2,473,046 (1981).Google Scholar
  24. 24.
    B. Lippert, J.Clin.Haem. and Oncol., 7(1), 26 (1977).Google Scholar
  25. 25.
    J.A. Broomhead, D.P. Fairlie and M.W. Whitehouse, Chem-Biol. Interactions, 31, 113 (1980).CrossRefGoogle Scholar
  26. 26.
    G.R. Gale, E.M. Walker, Jr., L.M. Atkins, A.B. Smith and S.J. Meischen, Res.Commun.Chem.Pathol.Pharmacol., 7, 529 (1974).PubMedGoogle Scholar
  27. 27.
    S.J. Meischen, G.R. Gale, L.M. Lake, C.J. Frangakis, M.G. Rosenblum, E.M. Walker, Jr., L.M. Atkins and A.B. Smith, J.Natl.Cancer Inst. 57, 841 (1976).PubMedGoogle Scholar
  28. 28.
    H.J. Ridgway, R.J. Speer, L.M. Halt, D.P. Stewart, A.D. Newman and J.M. Hill, J.Clin.Haematol.Oncol., 7, 220 (1977).Google Scholar
  29. 29.
    P. Schwartz, S.J. Meischen, G.R. Gale, L.M. Atkins, A.B. Smith and E.M. Walker, Jr., Cancer Treat. Rep., 61, 1519 (1977).PubMedGoogle Scholar
  30. 30.
    C.G. von Kralingen and J. Reedijk, Ciênc Biol (Portugal), 5, 159 (1980).Google Scholar
  31. 31.
    F. Basolo, H.B. Gray and R.G. Pearson, J.Amer.Chem.Soc., 82, 4200 (1960).CrossRefGoogle Scholar
  32. 32.
    Y. Kidani, M. Noji and T. Tashiro, Gann., 71, 637 (1980).PubMedGoogle Scholar
  33. 33.
    J.H. Burchenal, L. Lokys, J. Turkevich, G. Irani and K. Kern, Recent Results Cancer Res., 74, 146 (1980).PubMedGoogle Scholar
  34. 34.
    K.R. Harrap, M. Jones, C.R. Wilkinson, H. McD. Clink, S. Sparrow, B.C.V. Mitchley, S. Clark and A. Veasey, in Ref. (3), pg.193.Google Scholar
  35. 35.
    P. Lelieveld and L.M. Van Putten, Proc. 12th Int. Congr. Chemother. Abs., 21 (1981).Google Scholar
  36. 36.
    J.H. Burchenal, L. Lokys, J. Turkevich and C. Ramachandran, in Ref. (3), pg.113.Google Scholar
  37. 37.
    E.M. Walker, Jr. and G.R. Gale, Res.Commun.Chem.Pathol.Pharmacol., 6, 419 (1973).PubMedGoogle Scholar
  38. 38.
    R.J. Speer, H. Ridgway, D.P. Stewart, L.M. Hall, A. Zapata and J.M. Hill. J.Clin.Haematol.Oncol., 7, 210 (1977).Google Scholar
  39. 39.
    C.R. Gale, L.M. Atkins, S.J. Meischen and P. Schwartz, Cancer, 41, 1230 (1978).PubMedCrossRefGoogle Scholar
  40. 40.
    A.M. Guarino, U.S. Miller, S.T. Arnold, M.A. Urbanek, M.K. WolpertDe Filippes and M.P. Hacker, in Reference (3), pg.237.Google Scholar
  41. 41.
    J.E. Schurig, W.T. Bradner, J.B. Huftalen, G.J. Doyle and J.A. Gylys, in Reference (3), pg.227.Google Scholar
  42. 42.
    H. Calvert, personal communication.Google Scholar
  43. 43.
    K.R. Harrap, Platinum Analogues: Criteria for Selection, Series on Chemotherapy, Volume 1, (Ed. F.M. Muggia), Martinus Nijhoff, in press.Google Scholar

Copyright information

© Martinus Nijhoff Publishers, The Hague, Boston, London 1983

Authors and Affiliations

  • M. J. Cleare

There are no affiliations available

Personalised recommendations